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Abstract
 
Macrophage migration inhibitory factor (MIF) accounts for one of the first cytokine activities
to have been described, and it has emerged recently to be an important regulator of innate and
adaptive immunity. MIF is an upstream activator of monocytes/macrophages, and it is centrally
involved in the pathogenesis of septic shock, arthritis, and other inflammatory conditions. The
protein is encoded by a unique but highly conserved gene, and X-ray crystallography studies
have shown MIF to define a new protein fold and structural superfamily. Although recent
work has begun to illuminate the signal transduction pathways activated by MIF, the nature of
its membrane receptor has not been known. Using expression cloning and functional analysis,
we report herein that CD74, a Type II transmembrane protein, is a high-affinity binding pro-
tein for MIF. MIF binds to the extracellular domain of CD74, and CD74 is required for MIF-
induced activation of the extracellular signal–regulated kinase–1/2 MAP kinase cascade, cell
proliferation, and PGE
 
2
 
 production. A recombinant, soluble form of CD74 binds MIF with a
 
dissociation constant of 
 
 
 
9 
 
 
 
 10
 
 
 
9 
 
K
 
d
 
, as defined by surface plasmon resonance (BIAcore
analysis), and soluble CD74 inhibits MIF-mediated extracellular signal–regulated kinase activa-
tion in defined cell systems. These data provide a molecular basis for MIF’s interaction with
target cells and identify it as a natural ligand for CD74, which has been implicated previously in
signaling and accessory functions for immune cell activation.
Key words: cytokine • invariant chain • macrophage migration inhibitory factor • MAP kinase • 
receptor
 
Introduction
 
Macrophage migration inhibitory factor (MIF)
 
*
 
 is one of
the first cytokine mediators to have been described. Its ac-
tivity was defined in the mid 1960s by immunologists who
sought to replicate, in vitro, key features of cell-mediated
immunity
 
 
 
(1). MIF was identified to be a soluble, T cell–
derived factor in 1966
 
 
 
(2, 3), but the protein product re-
sisted biochemical characterization until its cloning in 1989
by David and colleagues (4). A mouse homologue was de-
scribed soon thereafter as a result of investigations into sys-
temically expressed regulators of glucocorticoid action (5).
Within a few years, both bioactive MIF protein and neu-
tralizing monoclonal antibodies were produced, and in
vitro and in vivo studies established MIF to play an impor-
tant role in the inflammatory cascade (6, 7).
MIF promotes monocyte/macrophage activation and it
is required for the optimal expression of TNF-
 
 
 
, IL-1, and
PGE
 
2 
 
(8–10). MIF-treated macrophages are more phago-
cytic and better able to destroy intracellular pathogens,
such as 
 
Leishmania
 
 
 
(11, 12). These activating functions have
been verified by papers in MIF-knockout mice
 
 
 
(9, 13, 14),
which have also revealed new activities such as the regula-
 
tion of TLR4 expression
 
 
 
(15). MIF’s role in adaptive immu-
nity is less well-characterized, but immunoneutralization of
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Abbreviations used in this paper:
 
 Alexa-MIF, Alexa-488–modified MIF;
ERK, extracellular signal–regulated kinase; MIF, macrophage migration
inhibitory factor; sCD74, soluble CD74.T
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Cloning of the MIF Receptor
 
MIF inhibits delayed-type hypersensitivity, T cell priming,
and antibody production in vivo (16, 17). MIF expression
contributes significantly to the immunopathology that re-
sults from excessive inflammation and autoimmunity (6, 7,
18), and its role in human disease has been emphasized by
the recent description of high-expression 
 
Mif
 
 alleles that are
linked to severe rheumatoid arthritis (19, 20).
MIF’s molecular mechanism of action appears to be
unique among proinflammatory cytokines. MIF broadly
counter-regulates the immunosuppressive effects of gluco-
corticoids (21–24), and at the subcellular level, it induces a
sustained pattern of extracellular signal–regulated kinase
(ERK)–1/2 MAP kinase activation (25) and maintains
proinflammatory function by inhibiting p53-dependent
apoptosis (10, 26). Despite evidence for an extracellular
mode of action, no cellular receptor for MIF has been de-
scribed. These circumstances have fueled interest in non-
classical mechanisms for ligand activation that have in-
cluded the role of an intrinsic catalytic activity (27–29) and
an endocytic pathway leading to a direct interaction be-
tween MIF and the transcriptional coactivator, Jab1 (30).
Using expression cloning and functional analysis, we re-
port the identification of CD74, the cell surface form of
the class II–associated invariant chain, as a cell surface
binding protein for MIF. MIF binds to CD74 by a high-
affinity interaction, and CD74 expression is required for
MIF-mediated ERK-1/2 phosphorylation, PGE
 
2
 
 produc-
tion, and cell proliferation.
 
Materials and Methods
 
Cytokines, Antibodies, and Mice. 
 
Human recombinant MIF
was prepared from an 
 
Escherichia coli
 
 expression system and puri-
fied free of endotoxin by methods described previously (31).
Conjugation of MIF to Alexa-488 (32) was performed by the
manufacturer’s protocol (Molecular Probes). Reaction conditions
were optimized to give an average dye/MIF (homotrimer) ratio
of 1:1, which was determined by matrix-assisted laser desorption
ionization mass spectrometry (33). Recombinant human IL-6 and
IFN-
 
 
 
 were obtained from R&D Systems.
Human anti–human CD74 mAbs (clones LN2 and M-B741)
were obtained from BD Biosciences, and dialyzed free of sodium
azide for MIF functional studies. Control studies established that
these antibodies do not cross react with recombinant MIF.
CD74-KO (34) and wild-type controls were obtained from Jack-
son ImmunoResearch Laboratories.
 
MIF Activity Assays. 
 
MIF-dependent phosphorylation of
ERK-1/2 (p44/p42) was measured by Western blotting of cell
lysates using specific antibodies directed against phospho-p44/
p42 or total p44/p42 (25). MIF-mediated suppression of apopto-
sis was assessed in serum-deprived, primary fibroblasts by im-
munoassay of cytoplasmic histone-associated DNA fragments
(Roche Biochemicals; references 10, 26). MIF’s tautomerase ac-
tivity was measured by visible spectrophotometry using 
 
l
 
-dopa-
chrome methyl ester as a substrate (35). MIF-induced secre-
tion of PGE
 
2
 
 secretion into medium was measured by specific
ELISA (10). Proliferation studies were performed by a modifica-
tion of previously published procedures (25). Human Raji B cells
(American Type Culture Collection) were cultured in RPMI
1640/10% FBS, plated into 96-well plates (500–1,000 cells/
 
well), and rendered quiescent by overnight incubation in RPMI/
0.5% FBS. The cells were washed, the RPMI 1640/0.5%
FBS was replaced, and the MIF and antibodies were added
as indicated. After an additional overnight incubation, 1 
 
 
 
Ci
[
 
3
 
H]thymidine was added and the cells were harvested 12 h later.
Fibroblast mitogenesis was examined in normal human lung fi-
broblasts (CCL210; American Type Culture Collection) cul-
tured in DMEM/10% FBS, resuspended in DMEM/2% serum,
and seeded into 96-well plates (1,500 cells/well) together with
MIF and antibodies as shown (Fig. 9 C). Isotype control or anti-
CD74 mAbs were added at a final concentration of 50 
 
 
 
g/ml.
Proliferation was assessed after overnight incorporation of
[
 
3
 
H]thymidine into DNA.
 
Flow Cytometry, Binding Analyses, and Confocal Microscopy.
 
2.5 
 
 
 
 10
 
5
 
 cells/ml THP-1 cells were cultured in RPMI 1640/
10% FBS with or without 1 ng/ml IFN-
 
 
 
 for 72 h. After wash-
ing, 5 
 
 
 
 10
 
5
 
 cells were resuspended in 0.1 ml of ice-cold PBS,
pH 7.4, and incubated with 200 ng of Alexa-488–modified MIF
(Alexa-MIF) at 4
 
 
 
C for 45 min. The cells were washed, main-
tained in ice-cold conditions, and subjected to flow cytometry
analysis (FACSCalibur™; Becton Dickinson). In selected experi-
ments, THP-1 monocytes or COS-7 transfectants were incu-
bated with Alexa-MIF together with 50 
 
 
 
g/ml anti-CD74 mAb
or an isotypic control mAb(36).
Confocal fluorescence microscopy of Alexa-MIF binding to
cells was performed with a laser scanning instrument (model LSM
510; Carl Zeiss MicroImaging, Inc.). THP-1 cells were incubated
with IFN-
 
 
 
 for 72 h and washed three times with PBS/1% FBS
before staining for 30 min (4
 
 
 
C) with 2 ng/
 
 
 
l Alexa-MIF or Al-
exa-MIF plus 50 ng/
 
 
 
l of unlabeled MIF. For double immuno-
fluorescence confocal microscopy, IFN-
 
 
 
–treated THP-1 cells
were resuspended in 0.5 ml PBS, pH 7.4, and 20 
 
 
 
g/ml Alexa-
MIF and 15 
 
 
 
g/ml anti-CD74 mAb (clone LN2) and were
added at 4
 
 
 
C for 1 h. After washing in ice-cold PBS/2% FBS, the
cells were resuspended in 0.1 ml PBS and a rhodamine-conju-
gated anti–mouse IgG was added at 0
 
 
 
C for 1 h. The samples
were washed, resuspended in 0.2 ml PBS, and 30-
 
 
 
l aliquots
were added to poly-
 
l
 
-lysine–coated slides followed by anti-fad
mounting medium (Vectashield; Vector Laboratories). Images
were analyzed by Metamorph Intensity Analysis software (Uni-
versal Imaging). The percent colocalization for each image was
derived from the number of positive pixels common to both im-
ages (Alexa-MIF/anti-CD74), divided by the number of positive
pixels within the Alexa-MIF image
 
 
 
(37). Six cells were analyzed
and the significance was determined by the paired Student’s t test
(independent variables).
 
cDNA Library Construction, Expression, and Cell Sorting.
 
cDNA was prepared from the poly(A)
 
 
 
 RNA of IFN-
 
 
 
–acti-
vated, THP-1 monocytes, cloned into the 
 
 
 
ZAP-CMV vector
(Stratagene), and 2.5 
 
 
 
g/ml DNA aliquots were transfected into
1.5 
 
 
 
 10
 
7
 
 COS-7 cells by the DEAE-dextran method (38). The
transfected cells were incubated with Alexa-MIF for 45 min at
4
 
 
 
C, washed, and the positively staining cells were isolated with
a cell sorter (Moflo; DakoCytomation; reference 36). In a typical
run, 1.5 
 
 
 
 10
 
7
 
 cells/ml were injected and analyzed at a flow rate
of 10
 
4
 
 cells/s. Recovery was generally 
 
 
 
90%. Plasmid DNA was
extracted from sorted cells using the Easy DNA kit (Invitrogen)
and transformed into 
 
E. coli
 
 XL-10 gold (Stratagene) for further
amplification. Purified plasmid DNA was retransfected into
COS-7 cells for an additional round of sorting. After four rounds
of cell sorting, 250 single colonies were picked at random and
the insert size was analyzed by PCR. Clones with inserts 
 
 
 
1.4
kb were individually transfected into COS-7 cells, and the MIFT
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binding activity was reanalyzed by flow cytometry and confocal
microscopy.
 
Protein–Protein Interaction Studies. 
 
Full-length and truncated
recombinant CD74 products were generated by PCR and sub-
cloned into the pcDNA 3.1/V5-HisTOPO expression vector
(Invitrogen). The fidelity of vector construction was confirmed
by DNA sequencing. For pull-down experiments
 
 
 
(30), a full-
length (V5-CD74
 
1–232
 
), NH
 
2
 
-terminal–truncated (V5-CD74
 
46–232
 
),
membrane-truncated (V5-CD74
 
1–72
 
), or vector control plas-
mid was transfected into 5 
 
 
 
 10
 
5
 
 COS-7 cells using cytofectin
(Bio-Rad Laboratories). The cells were harvested 48 h later, lysed
with RIPA buffer (150 mM NaCl, 1% NP-40, 0.5% deoxycho-
late, 0.1% SDS, and 50 mM Tris, pH 7.5), and the lysates were
centrifuged at 10,000 
 
g
 
 for 20 min. Supernatants containing the
V5-His–tagged CD74 proteins were incubated with 20 
 
 
 
l Ni-
NTA–agarose beads (QIAGEN), rocked at 4
 
 
 
C for 1 h, and the
beads were collected by centrifugation. After resuspension in PBS,
pH 7.4, the bound complexes were incubated with 2 
 
 
 
g/ml MIF
for 4 h at 4
 
 
 
C. The beads were spun down, resuspended in 1 ml
PBS, and washed an additional four times. After SDS-PAGE on
4–20% polyacrylamide gels, the precipitated complexes were ana-
lyzed by Western blotting for CD74 (V5 epitope) and MIF.
In vitro transcription and translation was performed using the
TNT Reticulocyte Lysate system (Promega). Full-length CD74
(1–232 aa) and three truncated CD74 constructs (1–72 aa, 1–109
aa, and 1–149 aa) were used as templates for coupled transcription
and translation in the presence of 
 
35
 
S-containing amino acids.
The binding of 
 
35
 
S-labeled CD74 to immobilized MIF was as-
sessed by a 3-h incubation at room temperature, as recommended
by the TNT protocol (Promega).
 
Expression, Purification, and Activity Studies of Soluble CD74
(sCD74).
 
 
 
Truncated, sCD74 proteins comprising the extracel-
lular domain (sCD74
 
73–232
 
) and the intracellular/transmembrane
domain (sCD74
 
1–72
 
) were amplified by PCR and ligated into the
pCR T7/CT TOPO F 
 
E. coli
 
 expression vector (Invitrogen). Af-
ter verification of the correct structures by DNA sequencing, the
recombinant CD74 proteins were expressed in 
 
E. coli
 
BL21(DE3)pLysS under IPTG induction. The sCD74 proteins
were isolated from 
 
E. coli
 
 lysates by standard methods involving
DEAE cellulose chromatography and Ni-NTA affinity chroma-
tography
 
 
 
(39). Both sCD74
 
73–232
 
 and sCD74
 
1–72
 
 showed single
bands by SDS-PAGE and silver staining.
The sCD74 proteins were evaluated for MIF binding by first
assessing their ability to inhibit MIF detection in an MIF sand-
wich ELISA (40). In brief, 96-well plates were coated with an
anti-MIF mAb (R&D Systems) at 20 ng/well. After washing,
MIF was added together with sCD74
 
1–72
 
 (intracellular and trans-
membrane domains) and sCD74
 
73–232
 
 (extracellular domain) as
shown (Fig. 5 C). After incubation at 4
 
 
 
C, the wells were
washed, blocked, and a biotinylated anti-MIF pAb (R&D Sys-
tems) added. The bound complexes were detected after incuba-
tion and washing by adding streptavidin-conjugated alkaline
phosphatase (1:60) and 
 
p
 
-nitrophenylphosphate as substrate.
Real-time binding of MIF to CD74 was measured by surface
plasmon resonance using a optical biosensor (model BIA 2000,
BIAcore; Amersham Biosciences). The SA sensor chips, amine
coupling kit, and BIA Evaluation software were obtained from
Amersham Biosciences. MIF or sCD74 was immobilized onto
the SA chips in accordance with prescribed methods
 
 
 
(41). A sur-
face reference to which no ligand was bound, or to which a
membrane protein contol (G protein 
 
  
 
) was bound, was in-
cluded in the analysis. The derivatized sensor chips were washed
and equilibrated in PBS (pH 7.4, 20 
 
 
 
l/min), and the ligands
were introduced at five serial dilutions in BIAcore running buffer
(150 mM NaCl, 20 mM Hepes, pH 7.4, 2.5 mM MgCl
 
2
 
, 1 mM
EDTA, 1 mM DTT, and 0.005% P20) in 60-
 
 
 
l injection vol-
umes and at a flow rate of 20 
 
 
 
l/min. Binding was measured at
25
 
 
 
C for 3 min, followed by 17 min of dissociation. Sensorgram
response data were analyzed in the BIA Evaluation Kinetics pack-
age and the equilibrium affinity constant calculated
 
 
 
(41).
 
Results
 
Alexa-MIF is Bioactive and Binds to Human Monocytes.
 
Our initial attempts to prepare an 
 
125
 
I-labeled MIF species
suitable for cell binding studies were frustrated by a loss of
MIF bio-activity. We found that linking the fluorescent
dye Alexa 488 (32) to recombinant MIF at low-molar den-
sity produced an MIF conjugate with full activity in two
cell-based assays: (a) stimulation of ERK-1/2 phosphoryla-
tion (Fig. 1 A), and (b) protection from apoptosis (Fig. 1
B). Additionally, Alexa conjugation of MIF did not signifi-
cantly influence MIF’s intrinsic tautomerase activity (Fig. 1
C), which is a useful surrogate for the retention of native
MIF structure (35).
Figure 1. Alexa-488–modified MIF (Alexa-MIF) shows retention of
MIF biological activity in established assays. (A) Dose-dependent activa-
tion of the p44/p42 (ERK-1/2) MAP kinase cascade in IFN- –pretreated
THP-1 monocytes (25). (B) Suppression of p53-dependent apoptosis in
primary human fibroblasts (reference 26; CM, complete medium; SFM,
serum-free medium). MIF or Alexa-MIF was added at 50 ng/ml. Data
shown are mean   SD of triplicate wells and are representative of three
independent experiments. (C) No difference in MIF’s intrinsic tau-
tomerase activity was observed in Alexa-MIF versus native (unconjugated)
MIF using l-dopachrome methyl ester as a substrate (35).T
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We observed the binding of Alexa-MIF to a subpopula-
tion of IFN- –activated human monocytes by flow cytom-
etry, and this binding activity was competed by the addi-
tion of excess, unlabeled MIF (Fig. 2 A). Confocal
microscopy and direct visualization of IFN- –treated
monocytes at 4 C also showed surface binding of Alexa-
MIF that was competed by a 25-fold excess of unlabeled
MIF. Cell-bound Alexa-MIF was internalized upon raising
the temperature to 37 C (Fig. 2 B).
Expression Cloning of Cell Surface MIF-binding Proteins.
Having prepared a labeled, bioactive form of MIF and
identified a cellular source of MIF binding activity, we next
constructed a mammalian expression library in the  ZAP-
CMV vector using cDNA from IFN- –activated, THP-1
monocytes. Library aliquots representing a total of 1.5  
107 recombinants were transfected into COS-7 cells, which
we had established previously to exhibit minimal detectable
binding activity of MIF (unpublished data), and the trans-
fectants analyzed for Alexa-MIF binding by flow cytometry.
Positively staining cell fractions were purified by high-
speed cell sorting, and the cDNA clones collected, ampli-
fied, and retransfected for additional rounds of cell sorting
(Fig. 3 A). Enumeration of the positively staining, sorted
cells showed a  400-fold enrichment in MIF binding ac-
tivity. After four rounds of selection, single colonies were
prepared in E. coli, and 250 colones were randomly picked
for analysis. We sequenced 50 clones bearing cDNA inserts
of  1.4 kb and found that 10 encoded the surface form of
the class II–associated invariant chain, CD74 (CD74), a 31–
41-kD Type II transmembrane protein(42). The individual
clones differed with respect to their total length, but each
was in the sense orientation and encoded a complete extra-
cellular and transmembrane domain (Fig. 3 B).
Structural Verification of MIF Binding to CD74.  To ver-
ify that CD74 is a cell surface binding protein for MIF,
we analyzed the binding of Alexa-MIF to COS-7 cells
transfected with a CD74 expression plasmid or a vector
control. The binding of Alexa-MIF to the CD74-express-
ing COS-7 cells was inhibited by excess, unlabeled MIF
(unpublished data), and by an anti-CD74 mAb directed
specifically against the extracellular portion of the protein
(Fig. 4 A). Two-color immunofluorescence confocal mi-
croscopy of THP-1 cells showed that MIF colocalized
with CD74 in a spacio-temporal specific manner (Fig. 4
B), and the percent colocalization was calculated by
Metamorph image analysis to be 69.2   12.0 (P   0.031,
n   6 cells).
We next sought biochemical evidence for an association
between CD74 and MIF by performing “pull-down” ex-
periments in cells expressing CD74. MIF was detected
by Western blotting of protein complexes precipitated
from cells that expressed a V5-tagged, full-length CD74
(V5-CD741–232), an NH2-terminal truncated CD74 (V5-
Figure 2. Fluorescence analysis of Alexa-MIF binding to cells. (A)
Flow cytometry analysis of the binding of Alexa-MIF to THP-1 mono-
cytes. Competition for Alexa-MIF binding was performed in the presence
of 20  g/ml of unlabeled MIF. (B) Direct visualization of Alexa-MIF
binding to THP-1 monocytes by confocal microscopy. THP-1 cells were
incubated with 1 ng/ml IFN-  for 72 h, and stained with Alexa-MIF
(left) or with Alexa-MIF plus a 25-fold excess of unlabeled rMIF (mid-
dle). Cell-bound Alexa-MIF was rapidly internalized upon shifting cells
from 4  to 37 C for 15 min (right). Magnification: 630.
Figure 3. Identification by expression cloning of CD74 as a cell surface
binding protein for MIF. (A) Progressive enrichment by fluorescence-
activated cell sorting of COS-7 cell transfectants showing MIF binding
activity. (B) Structure of CD74 (35-kD isoform), and 3 of 10 representa-
tive CD74 cDNA clones with MIF binding activity. IC, TM, and EC are
the intracellular, transmembrane, and extracellular domains, respectively.
M1 and M17 refer to two sites of alternative translation initiation (42).T
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CD7446–232), but not a membrane-truncated CD74 lacking
the extracellular domain (V5-CD741–72; Fig. 5 A). [35S]-
CD74 protein prepared by a transcription and translation–
coupled, reticulocyte lysate system also bound to MIF in
vitro, and a 40 amino acid region within the CD74 extra-
cellular domain (residues 109–149) appears important for
MIF binding activity (Fig. 5 B).
To further validate a significant binding interaction be-
tween CD74 and MIF, we expressed in E. coli and purified
to homogeneity truncated, soluble CD74 proteins (sCD74)
comprising the membrane-truncated extracellular domain
(sCD7473–232), or the intracellular plus transmembrane do-
mains (sCD741–72), and tested their ability to inhibit MIF
recognition by a sensitive, (two-antibody) sandwich ELISA
system. As shown in Fig. 5 C, the addition of sCD7473–232,
but not sCD741–72, inhibited MIF detection in a dose-
dependent fashion.
Real-time Binding Analysis of MIF to CD74 (BIAcore Anal-
ysis).  We determined the equilibrium rate constant for
MIF binding to CD74 by surface plasmon resonance, a
technique that measures real-time binding interactions by
changes in the refractive index of a biospecific surface (41).
Optical biosensor surfaces, or protein “chips,” were pre-
pared and BIAcore analysis of the binding interaction be-
tween MIF (surface-bound MIF) and sCD7473–232 revealed
an equilibrium dissociation constant Kd of 9.0   10 9 M
(Fig. 6). Complementary binding analysis using MIF in the
Figure 4. Fluorescence analysis of Alexa-MIF binding to CD74-
expressing cells. (A) Flow cytometry analysis of the binding of Alexa-MIF
to CD74-transfected versus control vector-transfected COS-7 cells (left),
and binding of Alexa-MIF to CD74-transfected COS-7 cells incubated
with anti-CD74 mAb (clone LN2) versus an isotypic mAb control (right,
con Ab). The anti-CD74 mAb, LN2, is reactive with an epitope residing
within 60 amino acids of the extracytoplasmic, COOH terminus of the
protein (48). mAbs were added at 50  g/ml, and the data shown are
representative of at least three independent experiments. (B) Confocal
microscopy images of a representative THP-1 cell (IFN- –pretreated)
double stained with Alexa-MIF (left) and a rhodamine-labeled anti-CD74
mAb (middle). The merged images with yellow areas indicate colocaliza-
tion of MIF and CD74 (right). The percent colocalization was calculated
to be 69.2   12.0 (P   0.0308, n   6 cells).
Figure 5. Biochemical evidence of MIF binding to CD74. (A) Cell-
expressed CD74 binds MIF as detected by CD74 pull-down. Membrane-
truncated CD74 (V5-CD741–72), full-length (V5-CD741–232), and NH2-
terminal truncated CD74 (V5-CD7446–232) cDNAs were expressed in the
pcDNA 3.1/V5-HisTOPO expression vector, transfected into COS-7
cells, and the protein products were precipitated by their expressed His
tag. CD74 expression and recovery were monitored by Western blotting
with anti-V5 (top). MIF was detected by Western blotting with anti-MIF
(bottom). Vector: cells transfected with an empty vector control. (B) MIF
binds to the extracellular domain of CD74 in vitro. 35S-CD74 protein
was prepared in a coupled transcription and translation reaction using the
different CD74 expression plasmids shown. Protein–protein interaction
was assessed by measuring bound radioactivity in 96-well plates that were
precoated with MIF (n   6 wells per experiment). The data shown are
representative of three experiments. (C) Soluble, extracellular domain
CD74 (sCD7473–232) but not membrane-truncated CD74 (sCD741–72) in-
hibits MIF detection by sandwich ELISA. Increasing concentrations of
MIF were captured by an immobilized anti-MIF mAb, followed by the
addition of the sCD74 species shown and a biotinylated anti-MIF pAb
(43). The bound complexes were detected with streptavidin-conjugated
alkaline phosphatase and p-nitrophenylphosphate as a substrate.T
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mobile phase and surface bound sCD7473–232 revealed a Kd
of 2.3   10 10 M (unpublished data). These values are in a
range that would be expected given the nanomolar con-
centrations of MIF that have been measured in the circula-
tion (40, 43). Nevertheless, these binding constants may be
somewhat lower than the values in vivo because native
CD74 is a trimer, and the sCD7473–232 construct we pre-
pared lacks the transmembrane domain that is implicated in
protein trimerization (44).
CD74 Mediates MIF Induction of ERK-1/2 Phosphoryla-
tion, PGE2 Production, and Proliferation.  MIF has been
shown to play an important role in the activation responses
of macrophages and fibroblasts, in part by inducing sus-
tained activation of the p44/p42 (ERK-1/2) protein kinase
cascade (10, 45). To assess the functional significance of
MIF binding to CD74, we examined the capacity of MIF
to stimulate p44/p42 phosphorylation in macrophages ob-
tained from mice genetically deficient in CD7434. MIF in-
duced the phosphorylation of ERK-1/2 in CD74 /  mac-
rophages, but not in CD74 /  macrophages (Fig. 7).
Moreover, there was no MIF-dependent increase in PGE2
production in CD74    macrophages when compared with
CD74    macrophages.
Activation of the p44/p42 kinase cascade is an early
event in a signaling pathway leading to mitogenesis, and in-
deed MIF can stimulate the proliferation of different cell
types under conditions of induced quiescence, or growth
arrest (10, 45–47). We examined the ability of MIF to in-
duce ERK-1/2 activation and downstream proliferative re-
sponses in the human Raji B cell line, which expresses
abundant cell surface CD74 (48). MIF stimulated the phos-
phorylation of ERK-1/2 in quiescent Raji cells, and this
effect was inhibited by two different anti-CD74 mAbs, as
well as by sCD74 (sCD7473–232, but not sCD741–72; Fig. 8,
A and B). The inhibitory effect of anti-CD74 on ERK-1/2
phosphorylation was associated with a significant decrease
in the MIF-stimulated proliferation of these cells (Fig. 8 C).
Of importance, control studies established that neither of
these two anti-CD74 mAbs (clone LN2 nor M-B741) cross
react with recombinant MIF (unpublished data). As an ad-
ditional control for this experiment, we tested the impact
of anti-CD74 on the known pathway of IL-6 induction of
the ERK-1/2 MAP kinase cascade (49). Western blot anal-
ysis showed that there was no effect of anti-CD74 on the
increased phospho-ERK-1/2 content of IL-6 stimulated
cells (unpublished data).
We also sought to evaluate the potential role of the
MIF–CD74 stimulation pathway in cells outside the im-
mune system. MIF addition extends the lifespan of pri-
mary murine fibroblasts (26), and both MIF’s mitogenic
effects and its induction of the ERK-1/2 signal transduc-
tion cascade have been characterized previously in this
cell type (25). Fibroblasts express CD74 (50, 51), and we
confirmed by flow cytometry the surface expression of
CD74 in CCL210 human lung fibroblasts (unpublished
data). MIF stimulates ERK-1/2 phosphorylation in these
cells, in agreement with published papers (25, 52), and
we found anti-CD74 mAb to significantly inhibit both
MIF-induced ERK-1/2 phosphorylation and mitogenesis
(Fig. 9 A–C). Together, these data indicate that the bind-
ing of MIF to CD74 is a required step in the stimulation
of ERK-1/2 phosphorylation and cellular proliferation
by MIF.
Figure 6. High-affinity binding of MIF to CD74 measured by real-
time, surface plasmon resonance (BIAcore analysis). Representative bio-
sensorgrams of the interaction between sCD74 (sCD7473–232) and an MIF
sensor chip as described in Materials and Methods (top). A control of MIF
interaction with the membrane-associated G protein,    (bottom).
Figure 7. CD74 mediates MIF stimulation of p44/p42 (ERK-1/2)
phosphorylation and PGE2 production in wild-type but not CD74-KO
macrophages. Thioglycolate-elicited peritoneal macrophages were ob-
tained from CD74 /  and CD74 /  mice, and 6   105 cells were stim-
ulated with the indicated concentrations of MIF for 2.5 h. Cells were
harvested, and the lysates were quantified for phospho-p44/p42 and total
p44/p42 using specific antibodies as described in Materials and Methods.
Supernatant PGE2 concentrations were measured by ELISA (10). Data
shown are representative of three independent experiments.T
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Discussion
Although the first biological activity attributed to MIF
was described in the mid 1960s, information regarding
MIF’s precise role in cell physiology and immunity has
emerged only in the last few years. Among recent findings
has been the determination that MIF is expressed by many
cell types including the monocyte/macrophage (8), which
historically had been considered to be the “target” of MIF
action (2, 3). MIF is present preformed in macrophages
(and in T cells) and it exerts important, autocrine/paracrine
activating effects upon its release (8, 17). Antibody neutral-
ization and signal transduction papers have supported the
view that MIF acts by engaging a cell surface receptor (8,
25, 26), however, the lack of information regarding candi-
date receptors has prompted investigations into nonclassical
or specialized modes of action. These have included the bi-
ological role of an intrinsic tautomerase activity (27, 53),
which may be vestigial (28), and an endocytic pathway that
involves a direct interaction between MIF and the tran-
scriptional regulator, Jab1 (30).
We experienced considerable difficulty in preparing a
bioactive, 125I-radiolabeled MIF, and in biosynthetically la-
beling the protein to a sufficiently high specific activity for
cell binding studies. Radioiodination methods result in the
adventitious oxidation of MIF’s free cysteine residues,
which need to be in a reduced state for cytokine bioactivity
(54). In contrast, we found that modification of MIF by Al-
exa-488 under mild conditions produced a fully bioactive
protein that enabled the expression cloning of CD74 as a
high-affinity, cell surface binding protein for MIF.
This work provides the first insight into a membrane re-
ceptor for MIF, and the proximate steps for signal trans-
duction may now be considered in the context of the mo-
lecular biology of CD74. A role for CD74 in the transport
of class II proteins from the endoplasmic reticulum to the
Golgi complex has been established (55); however, it also
is known that 2–5% of cellular CD74 is expressed on the
cell surface (48, 56). CD74 surface expression occurs inde-
pendently of class II and in a variety of different cell types
Figure 8. CD74 mediates MIF stimulation of
ERK-1/2 (p44/p42) phosphorylation and proliferation
of human Raji B cells. (A) MIF initiates ERK-1/2
phosphorylation, and (B) sCD7473–232 and anti-CD74
mAb inhibit MIF-induced ERK-1/2 phosphorylation
in Raji cells. Raji cells were stimulated with 50 ng/ml
MIF for 2.5 h in the presence of an irrelevant protein
(BSA), membrane-truncated CD74 (sCD741–72), extra-
cellular domain CD74 (sCD7473–232), an isotype con-
trol antibody (Con Ab), or two anti-CD74 mAbs
(clones M-B741 or LN2, each added at 50  g/ml).
Anti-CD63 mAb, which is directed to an irrelevant
Raji cell surface protein (63), also did not block MIF-
stimulated p44/p42 phosphorylation when compared
with anti-CD74 mAb (not depicted). (C) Anti-CD74
mAb inhibits MIF-induced Raji cell proliferation. Raji
cells were cultured as described in Materials and
Methods, and stimulated with rMIF as shown in the
presence of 50  g/ml of the indicated antibodies.
Anti-CD74 antibodies showed no effect on Raji cell
proliferation in the absence of added MIF (not depicted).T
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(50, 56). Of note, CD74-KO mice are developmentally
immunocompromised and show lymphoid abnormalities
beyond what would be expected from the protein’s function
as a class II chaperone (34). Recent works have identified
an accessory role for CD74 in immune cell stimulation,
and this function requires a chondroitin–sulfate-dependent
interaction between CD74 and CD44 (57, 58). CD44 is a
widely expressed and a polymorphic transmembrane pro-
tein with known tyrosine kinase activation properties
(59), and the horizontal recruitment of CD44 into an
MIF–CD74 complex may be necessary for MIF signal
transduction in some cell types. CD74 surface expression is
also known to be regulated by the length of the protein’s
NH2-terminal, intracellular domain, which varies depend-
ing on which of two in-phase initiation codons are used
(60). Whether this differential translation of CD74 mRNA
mediates cellular sensitivity to MIF will also be important
to investigate.
The intracellular portion of CD74 lacks sequence do-
mains that might be predicted to interact with downstream
signaling molecules. Thus, it is noteworthy that the expres-
sion of a truncated, CD74 intracellular domain alone has
been shown to initiate p65-RelA–dependent transcrip-
tional activation (61). The activating ligand for CD74 was
not been defined by these papers, and this activation path-
way appears to require the recruitment of additional intra-
cellular proteins (61). Like MIF, CD74 is a homotrimer
(62), and MIF engagement of CD74 may act to effect the
oligomerization or the stabilization of the intracellular do-
main that is necessary for downstream signaling. Thus, the
MIF binding activity of CD74 provides insight into the bi-
ology of CD74 outside of its role in the transport of class II,
and supports those papers that have defined an accessory
signaling function for CD74 in immune cell physiology
(57, 58, 61).
Whether the binding of MIF to CD74 accounts for all
of MIF’s cellular actions is unknown, and perhaps un-
likely in light of experiments suggesting a pathway for
MIF internalization and binding to Jab1 (30), and contin-
ued interest in the biological function of MIF’s NH2-ter-
minal, catalytic domain (28). Nevertheless, recent in vitro
and in vivo works have placed MIF in a pivotal position
for the control of innate immunity. MIF regulates the ex-
pression of TLR4 (15), which is the receptor for gram-
negative endotoxin, and the MIF release sustains proin-
flammatory function by inhibiting activation-induced,
p53-dependent apoptosis (10, 26). MIF’s importance in
the pathophysiology of infection also has been affirmed in
experimental animal models of sepsis, where anti-MIF
protects from death even when administered 8 h after in-
fectious insult (40). The recent finding that human MIF is
encoded by four functionally distinct alleles, and that the
high-expression alleles are associated with severe rheuma-
toid arthritis (19) further emphasize this cytokine’s impor-
tance in human inflammatory disease. Pharmacological
interference in the MIF-CD74 interaction may offer an
important new approach to the modulation of pathologic
inflammatory processes.
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Figure 9. CD74 mediates MIF stimulation of ERK-1/2 (p44/p42)
phosphorylation and proliferation of CCL210 human lung fibroblasts. (A)
MIF stimulates ERK-1/2 (p44/p42) phosphorylation, and (B) anti-CD74
mAb inhibits ERK-1/2 phosphorylation and proliferation of CCL210
human lung fibroblasts. Fibroblasts were stimulated with 50 ng/ml MIF
for 2.5 h in the presence of an isotype control antibody (Con Ab) or the
anti-CD74 mAb (clone LN2). (C) Anti-CD74 inhibits MIF-induced
proliferation of human fibroblasts. Cells were stimulated for 2.5 h with 50
ng/ml rMIF in the presence of a Con Ab or anti-CD74 mAb (clone
LN2), each at 100  g/ml. Proliferation results are the mean   SD of trip-
licate assays and are representative of at least three separate experiments.
Anti-CD74 antibodies showed no effect on the proliferation of lung fi-
broblasts in the absence of added MIF (not depicted).T
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